SCYX

2.3709.02%
AF

Ann F. Hanham

Independent Director

Dr. Ann F. Hanham, Ph.D., was a Founding and Managing Partner of BAR Capital Management, LLC. from December 2013 to March 2017. Dr. Hanham is a senior health care executive with experience working with both private and public companies. Dr. Hanham possesses a diverse background in global clinical and regulatory development, finance and corporate strategy. She has extensive experience in developing pharmaceutical, diagnostic and medical device products with a proven record of accomplishment of clinical and regulatory approvals, building businesses and creating shareholder value. Dr. Hanham served as a Managing Director of Burrill Venture Capital. She served as a Managing Director at Burrill International Group. She served as Chief Executive Officer at Adlyfe, Inc. From February 2000 to November 2013, Dr. Hanham served as a Managing Director and General Partner of Burrill & Company. Prior to Burrill & Company in February 2000, she co-founded and served as Vice President at Clinical and Regulatory Affairs of InterMune Inc. (formerly InterMune Pharmaceuticals). Prior to that, she served as the Senior Director for Oncology Product Development at Otsuka Pharmaceutical Co., Ltd. (Otsuka America Pharmaceuticals, Inc.) and the Medical Director at Celtrix Pharmaceuticals Inc from 1991 to 1995. Dr. Hanham has also worked at Becton Dickinson in both regulatory and clinical affairs for the monoclonal antibody program and as a regulatory toxicologist with the Health Protection Branch of Health and Welfare Canada. Since March 2017, Dr. Hanham has provided independent management consulting as a sole proprietor. She served as Managing Director of Burrill Life Sciences Capital Fund III, L.P. and Burrill Life Sciences Capital Fund II, L.P. From 1988 to 1991, she served as a Senior Manager for Medical Affairs at the Immunocytometry Systems Division of Becton Dickinson and Company. She serves as the Chairman of Adlyfe Inc. She served as Chairman of Supervisory Board at elbion NV and serves as its Member of the Supervisory Board. She serves as Independent Chairman of the Board HTG Molecular Diagnostics, Inc. since at January 2021. She served as the Chair of HTG Molecular Diagnostics, Inc. since March 7, 2017 until March 2019. Dr. Hanham serves as Lead Independent Director at HTG Molecular Diagnostics, Inc. from April 2019 until January 2021. Dr. Hanham serves as the Co-Chairman of Supervisory Board of Elbion AG. She has been a Director of HTG Molecular Diagnostics, Inc. since August 29, 2016. She served as Director at Acusphere, Inc. since 2013. She had been an Independent Director at Endocyte, Inc. from November 2004 until May 3, 2018 and serves as Independent Director of SCYNEXIS, Inc. from December 2008. She is a Board Observer of Cardiokine and XDx. Dr. Hanham serves as a Director of Aerovance, Inc., Adlyfe Inc., Waterstone Pharmaceuticals, Inc., Neosil, Inc. and Primera Biosystems Inc. She served as a Director of Biotie Therapies Corp. from November 2008 to April 15, 2010, Veritas Medicine Inc., Targacept Inc. from September 2005 to August 16, 2006, Immunicon Corp. from January 2001 to June 1, 2004 and BioMimetic Therapeutics Inc. (Formerly BioMimetic Pharmaceuticals) from May 2001 to September 2006. She served as Director of Logical Therapeutics, Inc., PrimeraDx Inc., Sention, Inc. and Taiwan Liposome Company, Ltd. Dr. Hanham was a Board Certified in Toxicology in 1986. She has few years of clinical/regulatory and investing experience in the biotechnology industry. Dr. Hanham holds a Ph.D. in biology from the University of British Columbia. She holds M.Sc. in biology from Simon Fraser University and B.Sc. from the University of Toronto.

Positions